A Mab A Case Study In Bioprocess Development Jun 2026
The outcome was a robust run, where the culture achieved a final titer of 4.5 g/L —a benchmark that makes the manufacturing economically viable.
The study centers on the transition from "traditional" process development to an enhanced QbD approach. It leverages guidelines from the International Council for Harmonisation (ICH), specifically (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System). A Mab A Case Study In Bioprocess Development
From this case study on Mab-X, the bioprocess development community can extract four universal lessons: The outcome was a robust run, where the
Fractogel EMD TMAE.
: Researchers use small-scale platforms like the ambr®15 to simulate large-scale manufacturing conditions. 3. Define the Design Space The outcome was a robust run
The outcome was a robust run, where the culture achieved a final titer of 4.5 g/L —a benchmark that makes the manufacturing economically viable.
The study centers on the transition from "traditional" process development to an enhanced QbD approach. It leverages guidelines from the International Council for Harmonisation (ICH), specifically (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System).
From this case study on Mab-X, the bioprocess development community can extract four universal lessons:
Fractogel EMD TMAE.
: Researchers use small-scale platforms like the ambr®15 to simulate large-scale manufacturing conditions. 3. Define the Design Space